Assessment of aortic stiffness by cardiovascular magnetic resonance following the treatment of severe aortic stenosis by TAVI and surgical AVR

Table 3 Preoperative baseline and 6 month follow-up measurements

	SAVR		TAVI
	Baseline	6 months	Baseline	6 months
Haemodynamics
Heart Rate (bpm)	64 ± 12	65 ± 11	65 ± 11	66 ± 15
Systolic BP (mmHg)	131 ± 23	133 ± 20	127 ± 28	134 ± 22
Number of Medications^a	1.3 ± 0.8	1.4 ± 0.8	1.2 ± 1.0	1.3 ± 1.0
Systemic Arterial Compliance^b	0.88 ± 0.3	0.74 ± 0.2*	0.81 ± 0.3	0.71 ± 0.2
Aortic Valve
Peak gradient (mmHg)^c	59 ± 20	32 ± 18***	54 ± 14	25 ± 13***
Z_va	3.9 ± 0.9	3.5 ± 0.8*	4.1 ± 1.6	3.0 ± 1.1**
Left Ventricle
Mass Index (g/m²)	80 ± 25	65 ± 16***	82 ± 22	68 ± 18***
EDVI (ml/m²)	95 ± 25	77 ± 14***	95 ± 25	86 ± 19*
EF (%)	52 ± 12	57 ± 8**	52 ± 13	55 ± 11

Abbreviations: EDVI end diastolic volume indexed to body surface area, EF ejection fraction, Zva valvuloarterial impedance
Paired t test to compare baseline and 6 months: *p < 0.05, **p < 0.01, ***p < 0.001
^adefined as any of: ACE inhibitor, angiotensin II receptor antagonist, β blocker, spironolactone, doxazosin, hydralazine, amlodipine, felodipine or bendrofluazide
^bDerived as stroke volume index / pulse pressure
^cDerived from CMR assessment

ISSN: 1532-429X